2023 New Treatment Grant - A/Prof Jennette Sakoff

Project Summary

This project aims to target pancreatic cancer through the inhibition of the aryl hydrocarbon receptor (AhR) pathway, which is known to promote disease initiation and proliferation. AhR is overexpressed in 80% of pancreatic tumours and associated with poor overall survival. The activation of AhR in pancreatic cancer contributes to tumour growth, suppresses the immune system, and promotes the formation of a protective fibrous barrier around the tumour, which can impede the efficacy of standard chemotherapy and immunotherapy. By developing novel AhR inhibitors, the project seeks to not only hinder tumour growth but to also modify the tumour microenvironment which in turn will sensitize the cancer to conventional therapies. The team has identified an AhR-inhibitor 'chemical-switch' that allows access to potent chemotherapeutics with a unique mechanism of action. Pre-clinical studies will be conducted to validate the effects of AhR inhibition on pancreatic cancer and the tumour microenvironment. Successful outcomes may lead to innovative treatment approaches, addressing the aggressive nature of pancreatic cancer and improving patient prognosis. Collaboration with experts from diverse disciplines will ensure a comprehensive and effective research endeavour.